Well-versed in regulation


Well-versed in regulation

25.07.2016 - Swedish rare disease expert Wilson Therapeutics AB has appointed global regulatory executive Rick Lilley as Chief Regulatory Officer.

Lilley, who received his BSc in microbiology and genetics as well as his PhD in molecular genetics from Queen Mary College, University of London, has held senior positions in regulatory affairs and drug development in Europe, Japan and USA for the last three decades. Most recently, he served as Senior VP and Head of Global Regulatory Affairs at US pharma company Vertex Pharmaceuticals. At Vertex, he was responsible for the global filings for the breakthrough orphan drug Orkambi. Prior to that, Lilley was VP and Head of Global Regulatory Affairs at Belgian biopharma UCB. He has also held senior regulatory positions at Johnson & Johnson, Shire and AstraZeneca.


25.02.2016 Chaim Hurvitz, who was president of Teva International Group from 2002 until 2010, joins the board of directors of Genoscience Pharma. The Marseille-based company develops cancer treatments.

© Genoscience Pharma

Hurvitz serves as the Chief Executive Officer of venture capital firm CH Health and has just taken over as chair of the board of Israeli clinical-stage specialty pharmaceutical company PolyPid Ltd. He is also been on the board of directors of Teva Pharmaceuticals since 2011.

Dr. Mahkam Zanganeh, Robert Duggan and Manmeet Soni, respectively the former chief operating officer, chief executive officer and chief financial officer of Pharmacyclics, are joining the board along with Hurvitz. Their arrival is accompanied by an undisclosed increase in capital.


17.02.2016 The Weizmann Institute has honoured Merck’s CEO and Chairman of the Executive Board Karl-Ludwig Kley with the prestigious Weizmann Award in the Sciences and Humanities.

© Merck

“Throughout your career, you have expressed support and encouragement for Israel science and scientists; have been an exceptional friend to the Weizmann Institute; and have spearheaded and advanced the technology transfer relationship between the Institute and  Merck with the goal of improving the lives of many people through better medical therapies,” Daniel Zajfman, President of the Weizmann Institute, explained the decision. Merck and the Weizmann Institute have been collaborating since 1978. 

The Weizmann Award in the Sciences and Humanities has been given out since 1966; notable awardees include Margaret Thatcher and Jacques Chirac. 


11.02.2016 Swiss immunooncology player Maxivax has appointed Dimitrios Goundis as its Chief Executive Officer. Before joining Maxivax, Goundis worked for The Medicines Company in various roles, among them Business Development and Global Head of R&D.

© Maxivax

Previously, the biochemist held the position of Chief Operating Officer at Speedel, and also worked in project management and research scientist position at F. Hoffman-La Roche, in the fields of immunology, oncology and CNS. Goundis holds a PhD in Biochemistry from the University of Oxford, a BSc (Hons) in Chemistry and Biochemistry from the University of London, and a certificate in investment management from the London Business School.


10.02.2016 Barcelona-based orphan disease specialist Minoryx Therapeutics has appointed Khalid Islam as the new chairman of its board of directors. Until 2014, Islam served as chairman and CEO of Gentium S.p.A., an Italian manufacturer of active pharmaceutical ingredients.

© Minoryx

Before taking over at Gentium, Islam was president and CEO Arpida AG, where he was instrumental in listing the of Swiss biopharma company on SWX. Before that, he worked in academia at University of London’s Imperial College and at Milan University. He has published more than 85 scientific articles and sits on the editorial board of Current Drug Discovery and Technologies. Islam is currently the chairman of US company Fennec and a member of the board of directors at Swedish Karolinska Development, Italian Molmed and Swedish OxThera. 


03.02.2016 Swedish CDMO Recipharm has appointed Anke Mollowitz as Key Account Director Europe. Mollowitz joins from German contract manufacturer Aenova Group, where she was Head of Customer Service.

© Recipharm

Mollowitz, who originally trained as translator and interpreter, worked in the machine manufacturing sector before joining Haupt Pharma Wülfing, an Aenova company, in 2005. After working as sales representative and project manager, she took the position as Head of Customer Service in 2013. Among other tasks she was responsible for acquisitions and business development within the Haupt Group.

At Recipharm, Mollowitz will be responsible for coordinating customer management and commercial aspects within the business management team.


01.02.2016 The position of head of the Bone Patient Value Unit at Belgian biopharma UCB, newly created just last year, has been filled. Pascale Richetta has taken on the job, and she will also serve as Executive Vice President and member of the Executive Committee at UCB.


Richetta has worked in the pharma sector for more than 20 years, most recently as Vice President Western Europe and Canada at AbbVie. Prior to that, she held several management positions at Abbott, GlaxoSmithKline, Ipsen and Servier. She studied medicine at the University of Poitiers, France.

At UCB, Richetta will be responsible for driving ahead the development of the company’s osteoporosis drug romosozumab.


27.01.2016 British drug developer e-Therapeutics plc has appointed Iain Ross as non-executive chairman. Ross holds similar appointments at Novogen, Biomer Technology, Anatara Life Sciences and several other companies.

© e-Therapeutics

Ross has worked in life science companies for more than 30 years. He was CEO of Celltech Biologics and CEO of Quadrant Healthcare. He also led Allergy Therapeutics towards its IPO and was Executive Chairman at Silence Therapeutics. Ross is Vice Chairman of the Council of Royal Holloway, London University.


25.01.2016 In mid-April, David Budd will join British biotech EpiStem as its new CEO and Director. Budd joins from Dx expert Leica Biosystems Amsterdam, where he worked as General Manager.

© EpiStem

Budd earned his Master's Degree in Molecular Biology from Canadian Queens University in 1992. He later served as Director of Marketing at Siemens Healthcare Diagnostics, Business Unit Leader at Bayer Diagnostics UK, and Sales Manager at Visible Genetics Inc., before joining Leica Biosystems as Commercial Director.


20.01.2016 After stepping down from his position of CEO at Medigene, Frank Mathias is taking over as CEO of Rentschler Biotechnologie, a contract manufacturer based in Laupheim, Germany. Former CEO Nikolaus F. Rentschler, owner of the company, is moving on to the Supervisory Board.

© vfa

After studying pharmacy, Mathias started out at Hoechst AG, from where he went on to become CEO of the German subsidiaries of Servier and Amgen. He then became CEO of Medigene in 2009. Mathias is chairman of the vfa-bio and has already spent year on Rentschler’s Supervisory Board.

18.01.2016 Klaus Peter Kaspar joined the board of Immunodiagnostic Systems Holdings plc in December. The biochemist has more than 35 years of experience in the field of diagnostics.


From 2005 to 2011, Kaspar worked at bioMérieux, where he held the positions of Head of the microbiology unit and Head of the Global Research and Development. Before that he worked for Roche Diagnostics, formerly Boehringer Mannheim GmbH in various positions in Strategy, Business Development and R&D Management. He also serves as director at Daktari Diagnostics and Magellan bioConsult.

Vorherige Seite5/37Nächste Seite


Current issue

All issues

Product of the week


Stock list

All quotes


  • MOLOGEN (D)1.75 EUR16.67%
  • RENEURON (UK)3.15 GBP5.00%


  • VECTURA (UK)148.80 GBP-4.25%


  • PROTHENA PLC (IE)52.22 USD47.2%
  • DBV TECHNOLOGIES (F)64.40 EUR26.3%


  • MOLOGEN (D)1.75 EUR-30.0%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SAREUM HOLDINGS (UK)0.62 GBP-19.5%


  • KARO BIO (S)29.80 SEK1774.2%
  • NICOX (F)11.20 EUR474.4%
  • SAREUM HOLDINGS (UK)0.62 GBP158.3%


  • BB BIOTECH (D)45.00 EUR-84.5%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 25.07.2016


All Events